Company / Operating Income
Xenon Pharmaceuticals Inc. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$373.1M
FY2025
5-year range
-$373.1M / -$79.0M
FY2021-FY2025
Trend
-33.6%
vs FY2024
Sector context
#173 of 204
Health Care
What the data says
Xenon Pharmaceuticals Inc.'s operating income of -$373M is lower than 85% of companies in the Health Care sector (FY2025). Operating Income has declined for 5 consecutive years, from -$31M in FY2020 to -$373M in FY2025.
Based on SEC 10-K filings.
-$373M in FY2025.
Declined from -$214M to -$373M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 15% in Health CareTop 85% of 204This company -$373.1M Sector average $107.7M
▼
-446.3% below sector average
Key checks
Key Insights
- Xenon Pharmaceuticals Inc.'s operating income has declined for 5 consecutive years.
- In FY2025, operating income decreased 33.6% year-over-year.
- Ranks #173 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.51 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$373.1M | -33.6% |
| FY2024 | -$279.3M | -30.5% |
| FY2023 | -$214.1M | -65.7% |
| FY2022 | -$129.1M | -63.5% |
| FY2021 | -$79.0M | -152.4% |
| FY2020 | -$31.3M | +26.9% |
| FY2019 | -$42.8M | -12.6% |
| FY2018 | -$38.0M | -306.4% |
| FY2017 | -$9.4M | +62.3% |
| FY2016 | -$24.8M | -165.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026